Sheridan Capital Partners Invests in Currier Plastics, Appoints New CEO to Drive Growth
Sheridan Capital Partners has officially completed its investment in Currier Plastics a leading manufacturer of precision-engineered plastic components primarily serving the healthcare and life sciences sectors. This milestone underscores Sheridan’s growing role as a strategic investor in healthcare, reflecting its commitment to supporting businesses that deliver innovative products and services across outsourced solutions, medical technologies, software, and pharmaceutical markets.
In conjunction with the investment, Currier announced the appointment of Andrew McLean as its new Chief Executive Officer, signaling the company’s readiness for its next phase of growth.
A Legacy of Innovation and Technical Expertise
Founded in 1982 and headquartered in Auburn, New York, Currier Plastics has built a strong reputation over more than four decades for delivering high-quality, custom plastic solutions to demanding industries. The company specializes in advanced blow molding and injection molding techniques, producing tight-tolerance components in ISO Class 7 and Class 8 cleanroom environments.
Beyond manufacturing, Currier offers an integrated portfolio of value-added services, including design engineering, material selection, and product assembly. This comprehensive capability set positions the company as a trusted partner for healthcare, pharmaceutical, and other regulated industries where precision, reliability, and compliance are critical.
Founder and President John Currier expressed pride in the company’s journey and optimism for the future with Sheridan’s backing. “I am very proud of what our dedicated employees have created at Currier, and we have found a great partner in Sheridan to continue our steadfast commitment to excellence for our customers. The healthcare expertise Sheridan brings will be invaluable as we look to execute on organic growth initiatives and strategic M&A. In addition, this partnership and the leadership of our incoming CEO Andrew McLean will enable us to continue to invest in the talent and operational resources to continue providing world-class products and services to our growing customer base across multiple end markets.”
Sheridan’s Investment Thesis
For Sheridan Capital Partners, the investment in Currier aligns with a long-standing focus on healthcare contract manufacturing. Co-founder and Partner Sean Dempsey highlighted the significance of the partnership: “Currier is the result of our multi-year thesis in medical contract manufacturing, and we are very excited to be partnering with them at this inflection point in their growth.”
Sheridan Principal Michael Bernard added that Currier’s consistent ability to attract and retain high-value customers demonstrates its excellence. “Currier continues to win new business from highly demanding customers for a reason. We are excited to add even more resources to Currier so it can be the best possible partner to its customers.”
Leadership Transition: Andrew McLean as CEO
The appointment of Andrew McLean as CEO marks a pivotal step in Currier’s growth strategy. McLean brings over 25 years of executive leadership in the medical device and pharmaceutical industries, with proven success in scaling businesses and enhancing profitability.
Most recently, McLean served as CEO & President of SteriPack Group, a global contract manufacturer specializing in medical device and pharmaceutical product design. He also held the role of CEO of Sirtex, an oncology-focused manufacturer of minimally invasive interventional solutions. Earlier in his career, McLean held senior commercial and strategic roles at BD (Becton, Dickinson and Company) and Pfizer, two global leaders in healthcare.
Commenting on his new role, McLean stated: “Currier’s excellent reputation for quality, technical capabilities, and customer service has been established over decades. I look forward to continuing and growing this legacy.
Advisors and Transaction Details
The transaction was supported by a team of advisors on both sides. For Sheridan Capital Partners, the deal was led by Sean Dempsey, Michael Bernard, Brian McGregor, and Dimitri Kallioras. Legal counsel was provided by McDermott Will & Schulte LLP, with William Blair serving as financial advisor. On the Currier side, Stout Capital acted as financial advisor, and Benesch, Friedlander, Coplan & Aronoff LLP provided legal counsel.
As is customary in private equity transactions of this nature, the financial terms of the investment were not disclosed.
